Newsroom

Sight Sciences Announces Positive Interim Clinical Results from Prospective, Multicenter Trial of the OMNI Surgical System in Open Angle Glaucoma

Data presented at the Women in Ophthalmology 2020 Virtual Summer Symposium

read more +
Sight Sciences Announces First Patients Enrolled in ORION: A Prospective, Multicenter Clinical Trial of the OMNI Surgical System in Pseudophakic, Mild-to-Moderate Glaucoma Patients

Trial to Provide Surgeons with Prospective, Standalone Clinical Data on Microinvasive Glaucoma Surgery

read more +
Sight Sciences Introduces the Next-Generation OMNI® Surgical System for Microinvasive Glaucoma Surgery

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the launch of its next-generation OMNI Surgical System for microinvasive glaucoma surgery (MIGS) procedures.

read more +
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D.

read more +
International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI® Surgical System Predicate Device (VISCO360®)

Sight Sciences, Inc., today announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚...

read more +
First International MIGS Data for the OMNI® Surgical System Presented at ESCRS

Sight Sciences announced clinical results from the first study of the OMNI® Surgical System in glaucoma patients were presented at the European Society of Cataract and Refractive Surgery (ESCRS). Findings from...

read more +
Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System

New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device company...

read more +
First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI™ Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures

MENLO PARK, Calif. – Sight Sciences today announced enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multi-center study to evaluate the safety and efficacy of the OMNI™...

read more +